Paradox Immunotherapeutics

Paradox Immunotherapeutics

Paradox Immunotherapeutics is a Toronto-based pharmaceutical company developing immunotherapies for rare diseases that cause organ failure. Using a proven-successful​
immunotherapy drug design platform, they design drugs that harness the body’s own​ immune system to clear lethal deposits from affected organs and reverse organ damage.​

The company is founded by the same team that designed PRX004, an immunotherapy to​ treat heart failure caused by transthyretin (ATTR) amyloidosis. PRX004 was licensed to​ Prothena Biosciences Inc. by University Health Network​ and entered FDA clinical trials in 2018 (NCT#03336580).​

Using the same platform technology, their current research pipeline includes a potential​ treatment for immunoglobulin light chain (AL) cardiac amyloidosis, another cause of heart​ failure for which no first-line therapy currently exists and a US market opportunity of​ ~$3.2B. With a team of experts in immunotherapy drug design, they possess an orphan​ drug discovery platform for the potential treatment of ~30 rare diseases, a platform​ technology which has already sparked the interest of major players in the pharmaceutical​ industry.

Natalie J. Galant,

Co-Founder, CEO
natalie@paradoximmuno.com

Yulong Sun,

Co-Founder, CSO
yulong@paradoximmuno.com